|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM29739505X |
| 003 |
DE-627 |
| 005 |
20231227130027.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2019 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2019.05.012
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1224.xml
|
| 035 |
|
|
|a (DE-627)NLM29739505X
|
| 035 |
|
|
|a (NLM)31121287
|
| 035 |
|
|
|a (PII)S1521-6616(19)30209-8
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Luo, Qin
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Interleukin 28 is a potential therapeutic target for sepsis
|
| 264 |
|
1 |
|c 2019
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 20.04.2020
|
| 500 |
|
|
|a Date Revised 13.12.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2019 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Identification of new therapeutic targets for the treatment of sepsis is imperative. We report here that cytokine IL-28 (IFN-λ) levels were elevated in clinical and experimental sepsis. Neutralization of IL-28 protected mice from lethal sepsis induced by cecal ligation and puncture (CLP), which was associated with improved bacterial clearance and enhanced neutrophil infiltration. Conversely, administration of recombinant IL-28 aggravated mortality, facilitated bacterial dissimilation and limited neutrophil recruitment, in the model of sepsis induced by CLP. This study defines IL-28 as a detrimental mediator during sepsis and identifies a potential therapeutic target for the immune therapy in sepsis
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Immunity
|
| 650 |
|
4 |
|a Infection
|
| 650 |
|
4 |
|a Interleukin-28
|
| 650 |
|
4 |
|a Neutrophil
|
| 650 |
|
4 |
|a Sepsis
|
| 650 |
|
7 |
|a Antibodies, Neutralizing
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a interferon-lambda, human
|2 NLM
|
| 650 |
|
7 |
|a IL28A protein, mouse
|2 NLM
|
| 650 |
|
7 |
|a Interleukins
|2 NLM
|
| 650 |
|
7 |
|a interferon-lambda protein, mouse
|2 NLM
|
| 700 |
1 |
|
|a Liu, Yi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Shuang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yin, Yibing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xu, Banglao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cao, Ju
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 205(2019) vom: 22. Aug., Seite 29-34
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:205
|g year:2019
|g day:22
|g month:08
|g pages:29-34
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2019.05.012
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 205
|j 2019
|b 22
|c 08
|h 29-34
|